Showing results (41-50 of 494) with videos related to
Sort By:
Pageof 50
The Lancet. Infectious Diseases|April 3, 2016
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approachJohn H Rex, Kevin OuttersonPlos Medicine|January 19, 2022
Reporting bias in clinical trials: Progress toward transparency and next stepsMayookha Mitra-Majumdar, Aaron S KesselheimAMA Journal of Ethics|October 28, 2021
How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?Beatrice L Brown, Aaron S KesselheimAnnals of Internal Medicine|September 4, 2008
Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005Aaron S Kesselheim, David M StuddertBioorganic & Medicinal Chemistry|September 5, 2016
Regulatory Incentives for Antibiotic Drug Development: A Review of Recent ProposalsMichael S Sinha, Aaron S KesselheimValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2021
International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral EffectsLeah Z Rand, Aaron S KesselheimFood and Drug Law Journal|August 26, 2015
A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges?Jonathan J Darrow, Aaron S KesselheimDrug Discovery Today|May 12, 2016
Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug developmentEvan S Caplan, Aaron S KesselheimAmerican Journal of Law & Medicine|November 1, 2017
Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant InfectionsThomas J Hwang, Aaron S KesselheimThe Hastings Center Report|March 17, 2017
Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social ConsiderationsSpencer Phillips Hey, Aaron S KesselheimPageof 50